Bloomberg Talks Quest Diagnostics CEO Jim Davis Talks Outlook
Feb 10, 2026
Jim Davis, CEO of Quest Diagnostics and leader in clinical lab testing, discusses chronic disease trends driving testing demand. He explores the rise of consumer prevention testing and partnerships. He highlights growth in the consumer segment and advances in oncology and early Alzheimer blood biomarkers.
AI Snips
Chapters
Transcript
Episode notes
Two Parallel Growth Engines
- Chronic disease testing (diabetes, autoimmune, cancer) continues to drive large, sustained lab volume for Quest Diagnostics.
- Consumer prevention testing is a fast-growing complement as Quest powers wellness through partnerships with Whoop, Aura, and others.
Prevention Is The Fastest Growing Segment
- Quest's consumer-facing and partner-driven segment is about $250M and grew >30% last year.
- Management expects this prevention and wellness segment to grow north of 20% and wants prevention to become two-thirds of their business over time.
Blood Tests Revolutionize Alzheimer’s Detection
- Blood-based biomarkers for Alzheimer's (amyloid, tau) enable much earlier detection than imaging or cognitive testing.
- Earlier detection matters because new therapies work best at earliest disease stages and primary care can now triage patients faster.